Immunotherapy/BCG Combo Boosts EFS in Non-Muscle Invasive Bladder Cancer

Watchdoq April 30, 2025

(MedPage Today) -- LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus Calmette-Guérin (BCG)...

Read Full Article